A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine

NCT01228552 Phase 3 UNKNOWN

The purpose of this study is to evaluate the efficacy and safety of intra-oral topical ketoprofen for the treatment of acute migraine.

Details

Lead sponsor	Behar, Caren, M.D.
Phase	Phase 3
Status	UNKNOWN
Enrolment	100
Start date	2011-12
Completion	2012-01

Conditions

• Migraine Disorders
• Migraine Headache
• Migraine
• Acute Migraine

Interventions

• Topical, intra-oral ketoprofen gel
• Placebo gel

Primary outcomes

• Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatment — Within 240 minutes post-treatment

Countries

United States